Market Snapshot
S&P Futures
3,809.5
Dow Futures
30,868
Nasdaq Futures
11,633.25
Arbutus Biopharma Corporation
(NASDAQ:ABUS)
$2.71
$0.01
0.37%
Arbutus Biopharma Corporation Chart
ABUS Stock Price Today
Arbutus Biopharma Corporation (ABUS) stock rallied over 0.37% intraday to trade at $2.71 a share on NASDAQ. The stock opened with a gain of 5.45% at $2.62 and touched an intraday high of $2.759, rising 0.37% against the last close of $2.7. The stock went to a low of $2.62 during the session.
Stock Snapshot
$2.7
Prev. Close
412.88 Million
Market Cap
$2.62
Day Low
$2.62
Open
148.43 Million
Number of Shares
$2.759
Day High
-
P/E ratio
-0.74
EPS (TTM)
1.04
Cash Flow per Share
4.92
Free Float in %
-0.28
Book Value
585,847
Volume
Arbutus Biopharma Corporation Historical Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| 2022-06-30 | $2.62 | $2.759 | $2.62 | $2.71 | 573,051 |
| 2022-06-29 | $2.57 | $2.7 | $2.52 | $2.7 | 553,700 |
| 2022-06-28 | $2.66 | $2.71 | $2.58 | $2.61 | 674,600 |
| 2022-06-27 | $2.8 | $2.86 | $2.63 | $2.68 | 928,600 |
| 2022-06-24 | $2.95 | $2.95 | $2.8 | $2.84 | 2,697,800 |
| 2022-06-23 | $2.75 | $2.94 | $2.72 | $2.92 | 1,222,700 |
| 2022-06-22 | $2.69 | $2.85 | $2.65 | $2.74 | 822,000 |
| 2022-06-21 | $2.7 | $2.86 | $2.68 | $2.72 | 1,331,200 |
| 2022-06-17 | $2.57 | $2.76 | $2.54 | $2.68 | 1,783,000 |
| 2022-06-16 | $2.48 | $2.61 | $2.39 | $2.57 | 1,295,300 |
Contact Details
Company Information
Employees-
Beta2.4
Sales or Revenue10.99 Million
5Y Sales Change49.10%
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
About Company
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Frequently Asked Questions
What is the current Arbutus Biopharma Corporation (ABUS) stock price?
Arbutus Biopharma Corporation (NASDAQ: ABUS) stock price is $2.71 as of the last check on Thursday, June 30. During the trading session, ABUS stock reached the peak price of $2.759 while $2.62 was the lowest point it dropped to.
ABUS's industry and sector of operation?
The NASDAQ listed ABUS is part of Biotechnology industry that operates in the broader Health Care sector. Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication.
Who are the executives of ABUS?
Pam Murphy
Investor Relations Consultant
Mr. William H. Collier
Pres, CEO & Director
Mr. David C. Hastings CPA
CFO & Chief Accounting Officer
Dr. Michael J. Sofia Ph.D.
Chief Scientific Officer
What is the ABUS stock price today?
ABUS stock traded closed the last session at $2.71, which is $0.01 or 0.37% lower than its previous close of $2.7. ABUS's current trading price is 40.41% lower than its 52-week high of $6.50 where as its distance from 52-week low of 1.93% is -58.31%.
How many employees does ABUS have?
Number of ABUS employees currently stands at -. ABUS operates from 701 Veterans Circle, Warminster, PA 18974, United States.
Link for ABUS official website?
Official Webiste of $ABUS is: https://www.arbutusbio.com
How do I contact ABUS?
ABUS could be contacted at ABUS operates from 701 Veterans Circle, Warminster, PA 18974, United States, or at phone #267 469 0914 and can also be accessed through its website.
How many shares of ABUS are traded daily?
ABUS stock volume for the day was 585,847 shares while in the previous session number of ABUS shares traded was 573,051 . The average number of ABUS shares traded daily for last 3 months was 1.21 Million.
How much did ABUS change today?
The percentage change in ABUS stock occurred in the recent session was 0.37% while the dollar amount for the price change in ABUS stock was $0.01.
What price range ABUS stock been trading in?
In the recent session, the day high for ABUS stock was $2.759 while the low for ABUS stock touched on the day was $2.62.
What is the market cap of ABUS currently?
The market value of ABUS currently stands at 412.88 Million with its latest stock price at $2.71 and 148.43 Million of its shares outstanding.